Oncology Central

Oncology Central, part of Taylor and Francis, is the online resource for #oncology professionals.

[Oncology Central @OncologyCentral]

Breakthrough in metastatic prostate cancer treatment: Adding targeted radiopharmaceutical therapy 177Lu-PSMA-617 to standard care at diagnosis reduces disease progression risk by 28%. Research led by @DrScottTagawa at @WeillCornell and @nyphospital shows promise for ~90% of patients. https://t.co/HeLFagP8IA
@Novartis

[Oncology Central @OncologyCentral]

Hear from Susan Hedlund (Biller Family Foundation) on how to improve patient outcomes, reduce symptom burden and create goal-concordant care by moving palliative and psychosocial support upstream >>> https://t.co/glQ2h0XAYf

[Oncology Central @OncologyCentral]

Adolescents and young adults with cancer face unique psychosocial challenges as a diagnosis disrupts critical life milestones such as education, relationships, career and family planning. Gain practical advice on supporting AYA patients in our latest opinion piece >>> https://t.co/jYH0pY8OEE

@AOSW @BloodCancerUnited @ElephantsandTea @NIH

[Oncology Central @OncologyCentral]

Mark your calendars! The 19th Annual Royal Marsden Breast Cancer Meeting returns to London on October 2nd. Register now >>> https://t.co/FclkKPyefx

@royalmarsdenNHS

[Oncology Central @OncologyCentral]

When an oncologist identifies that an adolescent or young adult (AYA) patient with cancer is experiencing mental health challenges, what steps should they take? Learn how to recognize the early warning signs, plus evidence-based interventions from 4 expert oncology social workers here >>> https://t.co/wMaELgy5z8
@AOSW @BloodCancerUnited @ElephantsandTea @NIH

[Oncology Central @OncologyCentral]

"The most effective palliative care isn't delivered at the end of life—it's integrated early in the cancer journey." Gain insights from Susan Hedlund (Sheri and Les Biller Family Foundation) on how to integrate palliative and psychosocial support into oncology practice
https://t.co/osXK3und3K

[Oncology Central @OncologyCentral]

💬 "The most effective cancer treatment plan is not simply the one that is medically optimal—it's the one that a patient is realistically able to access, navigate and complete." - @CancerCare's Angelique Caba
Read the full interview here >>> https://t.co/nVOLjKOW2A

[Oncology Central @OncologyCentral]

As BCMA-targeted therapies move into earlier treatment lines, clinicians face critical questions:
- How do we manage prolonged ICAHT?
- How do we sequence these therapies optimally?
- What strategies minimize long-term complications?

Download our latest eBook to gain practical guidance >>>https://t.co/6PhnpkdvZy

[Oncology Central @OncologyCentral]

BCMA-targeted therapies have revolutionized multiple myeloma treatment, but they bring new clinical challenges that require expert management strategies.

This comprehensive eBook addresses:
✅ Managing immune effector cell-associated hematotoxicity (ICAHT)
✅ How to expand post CAR T-cell therapy relapse options
✅ Key insights from ASCO 2026
#MultipleMyeloma #BCMA #Hematology

📥 Download your free copy: https://t.co/0PYyIOb9dT

[Oncology Central @OncologyCentral]

How can we effectively integrate palliative and psychosocial support into cancer care pathways? Read our latest exclusive interview to find out >>> https://t.co/ea4EnwEwjB

[Oncology Central @OncologyCentral]

A Phase II trial has demonstrated the safety and effectiveness of the oral drug avatrombopag in managing chemotherapy-induced thrombocytopenia (CIT). https://t.co/PfH6rhZjqq

[Oncology Central @OncologyCentral]

📘 NEW eBook: BCMA therapies are transforming multiple myeloma treatment, but how do we manage toxicities and effective clinical integration?

Download here >>>https://t.co/WUbkEUKC78

[Oncology Central @OncologyCentral]

“Immigration status and immigration-related fears affect cancer patients in ways that extend far beyond healthcare access alone.”

@CancerCare's Angelique Caba discusses how fear becomes a barrier to care & what healthcare institutions can do to support both patients & clinicians >>> https://t.co/L92tBX5K4r
@AOSW

[Oncology Central @OncologyCentral]

The i31-SLNB test has been found to more accurately stratifies patients under consideration for SLNB into groups based on risk of SLN positivity than the clinicopathologic-only MIA nomogram. Find out more here >>> https://t.co/Ab02XKqtC7

[Oncology Central @OncologyCentral]

🗣️"The study findings demonstrate that incorporating tumor biology through DecisionDx-Melanoma's i31-SLNB test result can improve risk assessment, helping clinicians better distinguish which patients with melanoma may safely avoid SLNB and which should consider having the surgery." - Rohit Sharma @mfldclinic

https://t.co/2yT8OdtRSP

[Oncology Central @OncologyCentral]

In our latest interview, Angelique Caba, MSW, LCSW-R from @CancerCare discusses:
✅ How immigration-related fears directly influence treatment adherence and outcomes
✅ Why early collaboration between physicians and oncology social workers is critical
✅ The difference between burnout and vicarious trauma in healthcare professionals
✅ Practical steps institutions can take to support both immigrant patients and clinical staff

https://t.co/hsLiW6VDaw

[Oncology Central @OncologyCentral]

Hear directly from two EMBARK trial investigators as they break down the Phase III results comparing enzalutamide-based regimens with androgen deprivation therapy alone in patients with high-risk biochemically recurrent prostate cancer.
This episode covers:
✅ Efficacy and safety outcomes from the randomized trial ✅ Patient-reported outcomes and quality of life implications ✅ Practical considerations for clinical implementation
https://t.co/dQFekzlPDL

[Oncology Central @OncologyCentral]

Adding pirtobrutinib to standard venetoclax-rituximab therapy extends PFS with manageable toxicity, according to new Phase III trial results presented at #EHA2026.
https://t.co/nxTvfq5s2T

#CancerResearch #CLL

[Oncology Central @OncologyCentral]

BRUIN CLL-322 trial data presented at #EHA2026 @EHA_Hematology shows triplet therapy with pirtobrutinib + venetoclax-rituximab significantly improves progression-free survival in relapsed/refractory patients.
@DrMDavids @DanaFarber
https://t.co/YddLYzuzL1
#CLL #Hematology

[Oncology Central @OncologyCentral]

🎙️ In this second episode of the Future Oncology podcast EMBARK series, trial investigators explore enzalutamide + ADT vs ADT alone in high-risk nonmetastatic castration-sensitive prostate cancer.
Key discussion points:
✅ Efficacy and safety outcomes from the randomized trial
✅ Patient-reported outcomes and quality of life implications
✅ Practical considerations for clinical implementation
🎧 Listen now: https://t.co/XN11Ym8AZk